Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

General and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Ocugen, Inc.

Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Ocugen reports progress in gene therapy trials amidst financial stability

Ocugen's Q1 2024 performance reflects a mix of financial stability and regulatory milestones.
The company's strengths lie in its promising gene therapy platform and efficient cost management.
Challenges include timeline pressures for upcoming trial updates and ongoing financial constraints.
Opportunities arise from market expansion potential, investor confidence, and strategic partnerships.

Ocugen reports strong Q3 progress with key approvals and financial stability

Ocugen's Q3 2024 earnings call highlighted notable achievements in clinical advancements, regulatory approvals, and financial stability, positioning the company for future growth.
With a focus on advancing key pipeline candidates and managing expenses effectively, Ocugen aims to capitalize on opportunities for expansion and partnership collaborations.
While facing challenges in meeting timelines and ensuring successful trial outcomes, Ocugen remains optimistic about the potential of its innovative therapies to address unmet medical needs.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The company's latest business update sounds all fine and good, but OCGN stock holders want to see some action, not just words. The post Ocugen Stock Is Well-Positioned, But Investors Want Results appeared first on InvestorPlace.

Ocugen Stock Is Well-Positioned, But Investors Want Results

Ocugen's apparent failure to prepare a U.S. trial for Covaxin, which will likely be necessary for FDA approval, bodes badly for OCGN stock. The post Ocugen Stock Still Looks Poised to Tumble appeared first on InvestorPlace.

Ocugen Stock Still Looks Poised to Tumble

In so many words, the story's unchanged with OCGN stock. An all or nothing bet, with more pointing to "nothing," it's still best to stay away.

Ocugen Stock Remains an All or Nothing Wager You Shouldn't Make

Los Angeles, California--(Newsfile Corp. - August 17, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ocugen, Inc. ("Ocugen" or "the Company") (NASDAQ: OCGN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between February 2, 2021 and June 10, 2021, inclusive (the...

DEADLINE TODAY: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Ocugen, Inc. and Encourages Investors with Losses in Excess of $500,000 to Contact the Firm

New York, New York--(Newsfile Corp. - August 17, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Ocugen, Inc. (NASDAQ: OCGN) alleging that the Company violated federal securities laws.Class Period: February 2, 2021 and June 10, 2021Lead Plaintiff Deadline: August 17, 2021No obligation or cost to you.Learn more about your recoverable losses in OCGN:https://www.kleinstocklaw.com/pslra-1/ocugen-inc-loss-submission-form?id=18611&from=5.

OCGN ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of August 17, 2021 in the Class Action Filed on Behalf of Ocugen, Inc. Limited Shareholders

New York, New York--(Newsfile Corp. - August 16, 2021) -  The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Ocugen, Inc. ("Ocugen") (NASDAQ: OCGN) between February 2, 2021 and June 10, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Eastern District of Pennsylvania. To get more information go...

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Ocugen, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 17, 2021 - OCGN

New York, New York--(Newsfile Corp. - August 16, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Ocugen, Inc. (NASDAQ: OCGN) between February 2, 2021 and June 10, 2021, inclusive (the "Class Period"), of the important August 17, 2021 lead plaintiff deadline.SO WHAT: If you purchased Ocugen securities during the Class Period you may be entitled to compensation without payment of any out of pocket...

Final Deadline Tuesday: Rosen, Leading Investor Counsel, Encourages Ocugen, Inc. Investors with Losses to Secure Counsel Before Important Tuesday Deadline in Securities Class Action - OCGN

Los Angeles, California--(Newsfile Corp. - August 16, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ocugen, Inc. ("Ocugen" or "the Company") (NASDAQ: OCGN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between February 2, 2021 and June 10, 2021, inclusive (the...

DEADLINE TOMORROW: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Ocugen, Inc. and Encourages Investors with Losses in Excess of $500,000 to Contact the Firm

New York, New York--(Newsfile Corp. - August 16, 2021) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Ocugen, Inc. ("Ocugen" or "the Company") (NASDAQ: OCGN) and certain of its directors on behalf of shareholders who purchased or otherwise acquired Ocugen securities between February 2, 2021 and June 10, 2021 (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site:...

OCGN Investor Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Ocugen, Inc. Investors of Class Action and Encourages Shareholders to Contact the Firm

NEW YORK, Aug. 13, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Ocugen, Inc. (NASDAQ: OCGN) between February 2, 2021 and June 10, 2021, inclusive (the "Class Period"), of the important August 17, 2021 lead plaintiff deadline. SO WHAT: If you purchased Ocugen securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

FINAL DEADLINE NOTICE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Ocugen, Inc. Investors With Losses To Secure Counsel Before Important Deadline In Securities Class Action - OCGN

OCGN stock is a mix of irrational exuberance related to its valuation, unrealistic hopes, continuous speculation and very poor fundamentals. The post Ocugen Now Relies Solely on a Continued Covid-19 Crisis appeared first on InvestorPlace.

Ocugen Now Relies Solely on a Continued Covid-19 Crisis

SAN DIEGO, Aug. 13, 2021 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that the Ocugen, Inc. class action lawsuit charges Ocugen, Inc. (NASDAQ: OCGN) and certain of its top executives with violations of the Securities Exchange Act of 1934 and seeks to represent purchasers of Ocugen securities between February 2, 2021 and June 10, 2021, inclusive (the "Class Period").  The Ocugen class action lawsuit (Nicanor v.

DEADLINE NEXT TUESDAY: Shareholders with Substantial Losses Have Opportunity to Lead the Ocugen, Inc. Class Action Lawsuit - OCGN

LOS ANGELES--(BUSINESS WIRE)---- $OCGN #investors--The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Ocugen, Inc. (OCGN)

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Ocugen, Inc. (OCGN)

Los Angeles, California--(Newsfile Corp. - August 13, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ocugen, Inc. ("Ocugen" or "the Company") (NASDAQ: OCGN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between February 2, 2021 and June 10, 2021, inclusive (the...

TUESDAY DEADLINE NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Ocugen, Inc. and Encourages Investors with Losses in Excess of $500,000 to Contact the Firm

New York, New York--(Newsfile Corp. - August 12, 2021) -  Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating potential claims involving directors and officers regarding possible breaches of fiduciary duties related to whether insiders caused their companies to make false and/or misleading statements and/or failed to disclose, among other things, that:Ocugen, Inc. (NASDAQ: OCGN)The company or its officers and directors made materially false and misleading statements and/or failed to disclose...

Moore Kuehn, PLLC Encourages Investors of OCGN to Contact Law Firm

Los Angeles, California--(Newsfile Corp. - August 12, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ocugen, Inc. ("Ocugen" or "the Company") (NASDAQ: OCGN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between February 2, 2021 and June 10, 2021, inclusive (the...

TUESDAY DEADLINE REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Ocugen, Inc. and Encourages Investors with Losses in Excess of $500,000 to Contact the Firm

SAN DIEGO--(BUSINESS WIRE)-- #OCGNstock--The suit alleges defendants issued false statements concerning Ocugen business and prospects, resulting in its stock trading at inflated prices.

DEADLINE NEXT WEEK: Investors with Substantial Losses Have Opportunity to Lead the Ocugen, Inc. Class Action Lawsuit – OCGN

Investors need to pay close attention to Ocugen (OCGN) stock based on the movements in the options market lately.

Implied Volatility Surging for Ocugen (OCGN) Stock Options

For OCGN stock to justify its present valuation, Covaxin will have to generate a significant amount of North American sales. If it doesn't the stock has a long way to fall.

A Bullish Outlook on Ocugen Is a Bearish Outlook on the Pandemic

Even while Ocugen changes up its strategy in the U.S., the company is pushing for approval elsewhere and OCGN stock can still move higher. The post Prepare for Another Pop to $15 With Ocugen Stock appeared first on InvestorPlace.

Prepare for Another Pop to $15 With Ocugen Stock

Ardelyx

Home Point Capital

NEW YORK, NY / ACCESSWIRE / August 9, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit.

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of OCGN, HMPT and ARDX

Los Angeles, California--(Newsfile Corp. - August 9, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ocugen, Inc. ("Ocugen" or "the Company") (NASDAQ: OCGN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between February 2, 2021 and June 10, 2021, inclusive (the...

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Ocugen, Inc. and Encourages Investors with Losses in Excess of $500,000 to Contact the Firm

Finally, a bit of good news for this oversold biotech.

Why Ocugen Is Rallying Today

Los Angeles, California--(Newsfile Corp. - August 6, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ocugen, Inc. ("Ocugen" or "the Company") (NASDAQ: OCGN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between February 2, 2021 and June 10, 2021, inclusive...

SHAREHOLDER ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Ocugen, Inc. and Encourages Investors with Losses in Excess of $500,000 to Contact the Firm

Activision Blizzard

360 Finance Inc - ADR

NEW YORK, NY / ACCESSWIRE / August 6, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit.

News for Ocugen, Inc. Stock (OCGN)